Source: Pharmaceutical Technology
Myrobalan will use the funds to develop drugs for treating ailments of the central nervous system (CNS). Credit: Billion Photos/Shutterstock.com.
Myrobalan Therapeutics has secured $24m in a Series A funding round to develop CNS therapeutics with restorative potential. Co-win Ventures led the financing round, with both new and current investors taking part.
The Guan Zi Equity Investment Partnership, AB Magnitude Ventures Group and 3E Bioventures Capital were among the participants.
The biotechnology company is focused on overcoming historical challenges in CNS drug development, such as the lack of established target biology.
Effective blood-brain barrier penetration and the viability of long-term treatment with a suitable and tolerable dosing regimen add to the challenges.
Myrobalan’s approach involves developing brain-penetrant, highly selective, orally available products.
“Propelled by our foundational science, strategic chemistry partnership, compelling preclinical data and strong investors, Myrobalan is in a unique position to advance its neurorestorative candidates into the clinic.”
The company’s new oral neurorestorative drugs fix damage and reinstate neural function in degenerative CNS ailments with high unmet needs.
Co-win Ventures managing partner Dr Xin Huang stated: “We are proud to support Myrobalan in their work to develop first-in-class neurorestorative therapies based on strong target biology and innovative drug design.
“And we are confident the Myrobalan team will continue advancing this rich pipeline into novel therapies. Myrobalan has the potential to change the narrative for patients with CNS disease.”